[go: up one dir, main page]

MX2010005039A - Derivados de quinolina y su uso como inhibidores de tirosina quinasa. - Google Patents

Derivados de quinolina y su uso como inhibidores de tirosina quinasa.

Info

Publication number
MX2010005039A
MX2010005039A MX2010005039A MX2010005039A MX2010005039A MX 2010005039 A MX2010005039 A MX 2010005039A MX 2010005039 A MX2010005039 A MX 2010005039A MX 2010005039 A MX2010005039 A MX 2010005039A MX 2010005039 A MX2010005039 A MX 2010005039A
Authority
MX
Mexico
Prior art keywords
compound
compounds
methods
psoriasis
atherosclerosis
Prior art date
Application number
MX2010005039A
Other languages
English (en)
Inventor
Johan Malm
Jacob Westman
Natalia Nekhotiaeva
Johan Wannberg
Ulrika Baeckman
Original Assignee
Clanotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clanotech Ab filed Critical Clanotech Ab
Publication of MX2010005039A publication Critical patent/MX2010005039A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con un compuesto de conformidad con la reivindicación (1) así como una sal farmacéuticamente aceptable de los mismos. Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz del compuesto. El compuesto es útil para el tratamiento de cáncer, retinopatía diabética, degeneración macular relacionada con la edad, inflamación, derrame cerebral, miocardio isquémico, aterosclerosis, edema macular o psoriasis.
MX2010005039A 2007-11-15 2008-11-14 Derivados de quinolina y su uso como inhibidores de tirosina quinasa. MX2010005039A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98814707P 2007-11-15 2007-11-15
EP07120799 2007-11-15
PCT/EP2008/065596 WO2009063070A2 (en) 2007-11-15 2008-11-14 Quinoline derivatives and their use as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2010005039A true MX2010005039A (es) 2010-07-30

Family

ID=39295948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005039A MX2010005039A (es) 2007-11-15 2008-11-14 Derivados de quinolina y su uso como inhibidores de tirosina quinasa.

Country Status (21)

Country Link
US (2) US8557843B2 (es)
EP (1) EP2220047B1 (es)
JP (1) JP5565841B2 (es)
KR (1) KR101572929B1 (es)
CN (1) CN103476755B (es)
AU (1) AU2008322858B2 (es)
BR (1) BRPI0820210A2 (es)
CA (1) CA2705820C (es)
DK (1) DK2220047T3 (es)
EA (1) EA018798B1 (es)
ES (1) ES2540219T3 (es)
HR (1) HRP20150583T1 (es)
HU (1) HUE025421T2 (es)
IL (1) IL205308A (es)
MX (1) MX2010005039A (es)
NZ (1) NZ585090A (es)
PL (1) PL2220047T3 (es)
PT (1) PT2220047E (es)
RS (1) RS54061B1 (es)
SI (1) SI2220047T1 (es)
WO (1) WO2009063070A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592592B2 (en) 2010-04-02 2013-11-26 Senomyx, Inc. Sweet flavor modifier
AU2012295255B2 (en) 2011-08-12 2016-04-21 Senomyx, Inc. Sweet flavor modifier
US9376393B2 (en) 2012-01-05 2016-06-28 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases
CA2963901A1 (en) 2014-11-07 2016-05-12 Senomyx, Inc. Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB0324270D0 (en) * 2003-10-16 2003-11-19 Univ Edinburgh Improved control of ES cell self-renewal and lineage specification, and medium therefor
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007139496A1 (en) * 2006-05-30 2007-12-06 Clanotech Ab Quinoline derivatives acting as tyrosine kinase inhibitors
WO2008119771A2 (en) * 2007-03-30 2008-10-09 Clanotech Ab Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CA2705820C (en) 2016-06-07
EP2220047A2 (en) 2010-08-25
SI2220047T1 (sl) 2015-07-31
KR101572929B1 (ko) 2015-11-30
JP5565841B2 (ja) 2014-08-06
AU2008322858B2 (en) 2013-05-02
ES2540219T3 (es) 2015-07-09
CA2705820A1 (en) 2009-05-22
JP2011503151A (ja) 2011-01-27
IL205308A0 (en) 2010-12-30
WO2009063070A2 (en) 2009-05-22
CN103476755A (zh) 2013-12-25
WO2009063070A3 (en) 2009-07-23
HRP20150583T1 (hr) 2015-07-31
NZ585090A (en) 2011-09-30
RS54061B1 (sr) 2015-10-30
EA018798B1 (ru) 2013-10-30
PT2220047E (pt) 2015-07-30
AU2008322858A1 (en) 2009-05-22
HUE025421T2 (en) 2016-02-29
DK2220047T3 (en) 2015-06-29
US8557843B2 (en) 2013-10-15
US8957092B2 (en) 2015-02-17
EA201000803A1 (ru) 2011-02-28
KR20100097158A (ko) 2010-09-02
US20140018388A1 (en) 2014-01-16
BRPI0820210A2 (pt) 2017-05-09
PL2220047T3 (pl) 2015-08-31
EP2220047B1 (en) 2015-05-06
US20110053976A1 (en) 2011-03-03
IL205308A (en) 2015-03-31
CN103476755B (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
JO2848B1 (en) Organic compounds
MX358961B (es) Compuestos de tetraciclina sustituidos con fluor en c7.
MX2009004699A (es) Compuestos de piridinona.
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
MX2013012588A (es) Inhibidores de cinasa.
MY207696A (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
WO2010129057A3 (en) Tetracycline compounds
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
PH12014500065A1 (en) A new therapeutical composition containing apomorphine as active ingredient
TN2015000324A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
WO2011025982A3 (en) Tetracycline compounds
MX364400B (es) Compuestos de tetraciclina.
EA201391524A1 (ru) Производные гликозида и их применение
WO2010132670A3 (en) Pentacycline compounds
MX2010005039A (es) Derivados de quinolina y su uso como inhibidores de tirosina quinasa.
WO2014001215A3 (en) 3-o-heteroaryl-ingenol
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
MX2011012340A (es) Quinolinas sustituidas para uso como inhibidores del factor de crecimiento endotelial vascular (vegf).
GEP20125574B (en) Fused pyrimidine derivatives as trpv3 modulators

Legal Events

Date Code Title Description
FG Grant or registration